Investor Hub

Novavax, Inc. is a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases.

Latest quarterly earnings
Latest quarterly earnings
Latest investor presentation
Latest investor presentation
Latest publications, posters & presentations
Our research
Annual report
Annual report
NASDAQ:NVAX
Loading data...
Stock details
Latest press releasesEvents & presentationsReports & financialsSEC filingsStock details & analyst coverage
Dec 11, 2023
Statement

Novavax’s Updated COVID-19 Vaccine Now Available as Only Option in Poland

Read full article
Download
Dec 11, 2023
Statement

Novavax’s Updated COVID-19 Vaccine Now Available in Germany

Read full article
Download
Dec 11, 2023
Statement

Novavax’s Updated COVID-19 Vaccine Now Available in Austria

Read full article
Download
All press releases
Why invest with us

We are a biotechnology company that promotes improved health globally through the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases.

Learn more
Lisa Dunkle

For much of my four-decade career, I’ve worked with biotech companies trying to solve significant health challenges, including HIV. Novavax is uniquely positioned to help end this pandemic with our protein-based vaccine. I believe in NVX-CoV2373 so much.
I came out of retirement to join the fight.

Lisa Dunkle
Vice President, Global Medical Lead for Coronavirus Vaccine
Governance documents
Get notifications for investor updates

Sign up for notifications from Novavax including upcoming events, webcasts, research updates, daily stock closings, SEC filings, and more.

Go to email subscription
Investor inquiries

Shareholders seeking information can contact investor relations at (240) 268-2022 or email us at [email protected]

Novavax corporate policy prohibits any employees, other than designated spokespersons, from communicating with its investors.